BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 32350591)

  • 1. Deep abscopal response to radiotherapy and anti-PD-1 in an oligometastatic melanoma patient with unfavorable pretreatment immune signature.
    Watanabe T; Firat E; Scholber J; Gaedicke S; Heinrich C; Luo R; Ehrat N; Multhoff G; Schmitt-Graeff A; Grosu AL; Abdollahi A; Hassel JC; von Bubnoff D; Meiss F; Niedermann G
    Cancer Immunol Immunother; 2020 Sep; 69(9):1823-1832. PubMed ID: 32350591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypofractionated radiotherapy combined with lenalidomide improves systemic antitumor activity in mouse solid tumor models.
    Onyshchenko K; Luo R; Rao X; Zhang X; Gaedicke S; Grosu AL; Firat E; Niedermann G
    Theranostics; 2024; 14(6):2573-2588. PubMed ID: 38646638
    [No Abstract]   [Full Text] [Related]  

  • 3. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.
    Zhang X; Niedermann G
    Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen.
    Sharabi AB; Nirschl CJ; Kochel CM; Nirschl TR; Francica BJ; Velarde E; Deweese TL; Drake CG
    Cancer Immunol Res; 2015 Apr; 3(4):345-55. PubMed ID: 25527358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin Facilitates Radiation-Induced Abscopal Effects in Conjunction with PD-1 Checkpoint Blockade Through CXCR3/CXCL10-Mediated T-cell Recruitment.
    Luo R; Firat E; Gaedicke S; Guffart E; Watanabe T; Niedermann G
    Clin Cancer Res; 2019 Dec; 25(23):7243-7255. PubMed ID: 31506388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1 Restrains Radiotherapy-Induced Abscopal Effect.
    Park SS; Dong H; Liu X; Harrington SM; Krco CJ; Grams MP; Mansfield AS; Furutani KM; Olivier KR; Kwon ED
    Cancer Immunol Res; 2015 Jun; 3(6):610-9. PubMed ID: 25701325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
    Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
    Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequence of αPD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses.
    Wei J; Montalvo-Ortiz W; Yu L; Krasco A; Ebstein S; Cortez C; Lowy I; Murphy AJ; Sleeman MA; Skokos D
    Sci Immunol; 2021 Apr; 6(58):. PubMed ID: 33837124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response.
    De Wolf K; Kruse V; Sundahl N; van Gele M; Chevolet I; Speeckaert R; Brochez L; Ost P
    J Transl Med; 2017 Jan; 15(1):21. PubMed ID: 28137295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of late concurrent hypofractionated radiotherapy in advanced melanoma patients failing anti-PD-1 monotherapy.
    Funck-Brentano E; Baghad B; Fort M; Aouidad I; Roger A; Beauchet A; Otmezguine Y; Blom A; Longvert C; Boru B; Saiag P
    Int J Cancer; 2020 Sep; 147(6):1707-1714. PubMed ID: 32083739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral Tcf1
    Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
    Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clonality of CD4
    Arakawa A; Vollmer S; Tietze J; Galinski A; Heppt MV; Bürdek M; Berking C; Prinz JC
    Front Immunol; 2019; 10():1336. PubMed ID: 31275310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
    Wei SC; Anang NAS; Sharma R; Andrews MC; Reuben A; Levine JH; Cogdill AP; Mancuso JJ; Wargo JA; Pe'er D; Allison JP
    Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22699-22709. PubMed ID: 31636208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer.
    Britschgi C; Riesterer O; Burger IA; Guckenberger M; Curioni-Fontecedro A
    Radiat Oncol; 2018 May; 13(1):102. PubMed ID: 29855323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
    Qian JM; Yu JB; Kluger HM; Chiang VL
    Cancer; 2016 Oct; 122(19):3051-8. PubMed ID: 27285122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
    Wei SC; Levine JH; Cogdill AP; Zhao Y; Anang NAS; Andrews MC; Sharma P; Wang J; Wargo JA; Pe'er D; Allison JP
    Cell; 2017 Sep; 170(6):1120-1133.e17. PubMed ID: 28803728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy.
    Marciscano AE; Ghasemzadeh A; Nirschl TR; Theodros D; Kochel CM; Francica BJ; Muroyama Y; Anders RA; Sharabi AB; Velarde E; Mao W; Chaudhary KR; Chaimowitz MG; Wong J; Selby MJ; Thudium KB; Korman AJ; Ulmert D; Thorek DLJ; DeWeese TL; Drake CG
    Clin Cancer Res; 2018 Oct; 24(20):5058-5071. PubMed ID: 29898992
    [No Abstract]   [Full Text] [Related]  

  • 18. Adding liposomal doxorubicin enhances the abscopal effect induced by radiation/αPD1 therapy depending on tumor cell mitochondrial DNA and cGAS/STING.
    Wang L; Luo R; Onyshchenko K; Rao X; Wang M; Menz B; Gaedicke S; Grosu AL; Firat E; Niedermann G
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37640480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Low-Dose Radiation Therapy on Abscopal Responses to Hypofractionated Radiation Therapy and Anti-PD1 in Mice and Patients With Non-Small Cell Lung Cancer.
    Yin L; Xue J; Li R; Zhou L; Deng L; Chen L; Zhang Y; Li Y; Zhang X; Xiu W; Tong R; Gong Y; Huang M; Xu Y; Zhu J; Yu M; Li M; Lan J; Wang J; Mo X; Wei Y; Niedermann G; Lu Y
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):212-224. PubMed ID: 32417411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the Abscopal Effect With Anti-PD1 Therapy in Patients With Metastatic Solid Tumors.
    Ribeiro Gomes J; Schmerling RA; Haddad CK; Racy DJ; Ferrigno R; Gil E; Zanuncio P; Buzaid AC
    J Immunother; 2016; 39(9):367-372. PubMed ID: 27741091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.